Please login to the form below

Not currently logged in
Email:
Password:

gemcitabine

This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.

NICE knocks-back Shire's pancreatic cancer drug Onivyde

NICE knocks-back Shire's pancreatic cancer drug Onivyde

The watchdog was reviewing the treatment’s use in England and Wales for metastatic pancreatic cancer that has progressed after gemcitabine-based therapy.

Latest news

More from news
Approximately 1 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    cells. A good example of this is the combined use of  Abraxane and  gemcitabine in the treatment of  metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages  apoptosis of cell DNA.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics